IDXGD · Interpace Biosciences, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $36.14M | $38.73M | $46.93M | $40.04M | $5.68M | $8.2M | $32.4M | $24.22M | $21.9M | $15.9M | $13.09M | $9.43M | $119.94M | $146.53M | $126.9M | $157.29M | $134.59M | — | |
| -$55K | — | — | -$112K | -$158K | -$496K | — | — | — | — | — | — | — | — | — | — | — | — | |
| $13.1M | $14.6M | $17M | $14.98M | $13.61M | $14.31M | $21.67M | $15.89M | $10.2M | $7.36M | $6.64M | $6.91M | $1.27M | — | — | — | — | — | |
| $23.04M | $24.13M | $29.93M | $25.06M | $18.23M | $18.8M | $10.73M | $8.33M | $11.7M | $8.54M | $6.44M | $2.52M | $206K | $23.51M | $26.86M | $32.47M | $26.55M | — | |
| — | 62.31% | 63.77% | 62.58% | 321.08% | 229.39% | 33.1% | 34.4% | 53.43% | 53.71% | 49.25% | 26.74% | 0.17% | 16.04% | 21.17% | 20.64% | 19.73% | — | |
| $594K | $642K | $676K | $636K | $703K | $1.49M | $2.8M | $2.81M | $2.12M | $1.46M | $1.65M | $2.29M | $255K | — | — | — | — | — | |
| $8.58M | $9.92M | $11.66M | $10.23M | $9.13M | $9.18M | $9.25M | $11.12M | $8.42M | $6.57M | $5.46M | $10.36M | $604K | — | — | — | — | — | |
| $9.7M | $9.48M | $9.49M | $9.36M | $10.97M | $10.71M | $18.19M | $14.36M | $8.68M | $9.15M | $10.5M | $16.92M | $14.31M | — | — | — | — | — | |
| — | — | — | $900K | $1.3M | $3.2M | $4.5M | $4M | $3.6M | $3.25M | $3.77M | $3.81M | $773K | $0 | $900K | $900K | — | — | |
| $474K | $425K | $300K | $1.03M | $2.56M | $5.37M | $5.5M | $4.52M | $3.8M | $3.69M | $4.48M | $5.03M | $2.39M | $1.43M | $2.03M | $3.05M | $1.83M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $706K | $392K | $2M | $1M | |
| $18.87M | $20.05M | $21.82M | $21.1M | $21.85M | $25.14M | $36.79M | $34.77M | $24.33M | $14.83M | $12.89M | $42.93M | $18.03M | $24.94M | $52.09M | $37.17M | $33.46M | — | |
| $4.17M | $4.08M | $8.11M | $3.96M | -$3.62M | -$6.34M | -$26.07M | -$26.44M | -$12.63M | -$6.29M | -$6.44M | -$40.41M | -$17.83M | -$1.44M | -$25.23M | -$4.7M | -$6.9M | — | |
| — | 10.55% | 17.28% | 9.88% | -63.7% | -77.3% | -80.46% | -109.15% | -57.7% | -39.59% | -49.23% | -428.41% | -14.86% | -0.98% | -19.88% | -2.99% | -5.13% | — | |
| $4.64M | $4.51M | $8.41M | $4.98M | -$1.06M | -$962K | -$20.57M | -$21.91M | -$8.83M | -$2.6M | -$1.96M | -$35.38M | -$15.44M | -$12K | -$23.2M | -$1.66M | -$5.07M | — | |
| $543K | — | — | — | — | — | $549K | $440K | $331K | $433K | — | — | $602K | $0 | — | — | — | — | |
| — | — | — | -$667K | -$1.21M | -$366K | $467K | $196K | $263K | -$2.13M | $14K | -$93K | -$68K | -$59K | -$28K | -$14K | $120K | — | |
| — | — | $8.1M | $2.8M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $4M | $3.77M | $6.95M | $2.28M | -$5.84M | -$7.74M | -$26.15M | -$26.68M | -$12.7M | -$13.13M | -$8.57M | -$44.21M | -$18.5M | -$1.5M | -$25.26M | -$4.72M | -$6.78M | — | |
| -$20.86M | -$21.21M | $4000 | $17K | $29K | -$705K | $53K | -$28K | $18K | -$395K | -$162K | -$13.14M | -$5.03M | $180K | $208K | -$939K | $392K | — | |
| $24.45M | $24.58M | $6.7M | $1.95M | -$21.96M | -$14.94M | -$26.45M | -$26.74M | -$12.7M | $12.55M | -$22M | -$13.62M | -$16.77M | -$4.57M | -$25.53M | -$11.91M | -$6.81M | — | |
| — | 63.46% | 14.28% | 4.88% | -386.72% | -182.3% | -81.64% | -110.4% | -58.02% | 78.96% | -168.15% | -144.43% | -13.98% | -3.12% | -20.12% | -7.57% | -5.06% | — | |
| — | $24.58M | $6.24M | $1.95M | — | -$14.94M | -$29.48M | -$27.17M | -$12.7M | — | — | — | — | — | — | — | — | — | |
| -$927K | — | — | — | — | — | — | — | — | — | -$8.33M | -$11.36M | -$16.07M | -$4.56M | -$25.53M | -$11.91M | — | — | |
| USD/shares | $5.36 | $5.55 | $1.42 | $0.45 | -$5.18 | -$3.61 | — | — | — | — | — | — | — | — | — | -$0.83 | -$0.48 | — |
| USD/shares | $1.01 | $0.89 | $0.40 | $0.45 | -$5.18 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 4.42M | 4.39M | 4.32M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 15.77M | 1.82M | 1.55M | 14.9M | 14.72M | 14.59M | 14.44M | 14.31M | — |
| shares | — | 27.7M | 15.73M | 4.36M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 15.77M | 1.82M | 1.55M | 14.9M | 14.72M | 14.59M | 14.44M | 14.31M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2015: $984K in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 12 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $38,728,000 | $46,926,000 | $40,036,000 |